JP2011513476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513476A5 JP2011513476A5 JP2010550262A JP2010550262A JP2011513476A5 JP 2011513476 A5 JP2011513476 A5 JP 2011513476A5 JP 2010550262 A JP2010550262 A JP 2010550262A JP 2010550262 A JP2010550262 A JP 2010550262A JP 2011513476 A5 JP2011513476 A5 JP 2011513476A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- independently
- nhr
- ring atoms
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000006413 ring segment Chemical group 0.000 claims 20
- 125000005842 heteroatom Chemical group 0.000 claims 15
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 12
- 208000010877 cognitive disease Diseases 0.000 claims 10
- 206010012289 Dementia Diseases 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 7
- 208000028698 Cognitive impairment Diseases 0.000 claims 6
- 208000002705 Glucose Intolerance Diseases 0.000 claims 6
- 206010022489 Insulin Resistance Diseases 0.000 claims 6
- 208000019022 Mood disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 201000001119 neuropathy Diseases 0.000 claims 6
- 230000007823 neuropathy Effects 0.000 claims 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims 6
- 125000001931 aliphatic group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 208000017194 Affective disease Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 4
- 208000004930 Fatty Liver Diseases 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 230000036506 anxiety Effects 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 claims 2
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 claims 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims 2
- 208000004611 Abdominal Obesity Diseases 0.000 claims 2
- 208000036487 Arthropathies Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010065941 Central obesity Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000014311 Cushing syndrome Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 2
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010033307 Overweight Diseases 0.000 claims 2
- 208000016222 Pancreatic disease Diseases 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 2
- 201000009916 Postpartum depression Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 206010063661 Vascular encephalopathy Diseases 0.000 claims 2
- CGFNFWYVMWRXRK-UHFFFAOYSA-N [3-[[4-(4-fluorophenyl)piperidin-1-yl]methyl]-4-thiophen-3-ylpyrrolidin-1-yl]-(5-pyridin-2-ylthiophen-3-yl)methanone Chemical compound C1=CC(F)=CC=C1C1CCN(CC2C(CN(C2)C(=O)C=2C=C(SC=2)C=2N=CC=CC=2)C2=CSC=C2)CC1 CGFNFWYVMWRXRK-UHFFFAOYSA-N 0.000 claims 2
- AINSZMYEHLRMMD-UHFFFAOYSA-N [5-[2-[4-(1-hydroxyethyl)anilino]pyrimidin-4-yl]thiophen-3-yl]-morpholin-4-ylmethanone Chemical compound C1=CC(C(O)C)=CC=C1NC1=NC=CC(C=2SC=C(C=2)C(=O)N2CCOCC2)=N1 AINSZMYEHLRMMD-UHFFFAOYSA-N 0.000 claims 2
- VODWXIYHKVUFBI-UHFFFAOYSA-N [5-[2-[4-(1-hydroxyethyl)anilino]pyrimidin-4-yl]thiophen-3-yl]-piperidin-1-ylmethanone Chemical compound C1=CC(C(O)C)=CC=C1NC1=NC=CC(C=2SC=C(C=2)C(=O)N2CCCCC2)=N1 VODWXIYHKVUFBI-UHFFFAOYSA-N 0.000 claims 2
- RWSUFOQPPXINGD-UHFFFAOYSA-N [5-[2-[4-(1-hydroxyethyl)anilino]pyrimidin-4-yl]thiophen-3-yl]-pyrrolidin-1-ylmethanone Chemical compound C1=CC(C(O)C)=CC=C1NC1=NC=CC(C=2SC=C(C=2)C(=O)N2CCCC2)=N1 RWSUFOQPPXINGD-UHFFFAOYSA-N 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000002411 adverse Effects 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 230000001668 ameliorated effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000025748 atypical depressive disease Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 208000006132 lipodystrophy Diseases 0.000 claims 2
- 230000003340 mental effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000003077 normal pressure hydrocephalus Diseases 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000019899 phobic disease Diseases 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 230000003820 β-cell dysfunction Effects 0.000 claims 2
- OMECRZCEDFNFBE-UHFFFAOYSA-N (4-ethylpiperazin-1-yl)-[5-[2-[4-(1-hydroxyethyl)anilino]pyrimidin-4-yl]thiophen-3-yl]methanone Chemical compound C1CN(CC)CCN1C(=O)C1=CSC(C=2N=C(NC=3C=CC(=CC=3)C(C)O)N=CC=2)=C1 OMECRZCEDFNFBE-UHFFFAOYSA-N 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- -1 pyrrolidino, piperidino, piperazino, morpholino Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 0 *C(c1c(*)[s]c(*)c1I=N)=N Chemical compound *C(c1c(*)[s]c(*)c1I=N)=N 0.000 description 22
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- KDTVWEHAAISPNW-UHFFFAOYSA-N CN1CCSCC1 Chemical compound CN1CCSCC1 KDTVWEHAAISPNW-UHFFFAOYSA-N 0.000 description 2
- GIEHADAJFYOEBK-VZUCSPMQSA-N C/C=C(/CC1N(C)CCCC1)\C=C Chemical compound C/C=C(/CC1N(C)CCCC1)\C=C GIEHADAJFYOEBK-VZUCSPMQSA-N 0.000 description 1
- JDARZYAWYCVJGU-UHFFFAOYSA-N CC(C)(CC1)CCN1C(c1c[s]c(-c2c[nH]nc2)c1)=[U] Chemical compound CC(C)(CC1)CCN1C(c1c[s]c(-c2c[nH]nc2)c1)=[U] JDARZYAWYCVJGU-UHFFFAOYSA-N 0.000 description 1
- QBTNTXPKFWFXIG-UHFFFAOYSA-N CC(C)(CCC1)CCN1C(c1c[s]c(-c2c(C)[nH]nc2)c1)=O Chemical compound CC(C)(CCC1)CCN1C(c1c[s]c(-c2c(C)[nH]nc2)c1)=O QBTNTXPKFWFXIG-UHFFFAOYSA-N 0.000 description 1
- BOSQREDAJQASQH-UHFFFAOYSA-N CC(C)(CCC1)CCN1C(c1c[s]c(-c2c(C)[nH]nc2C)c1)=O Chemical compound CC(C)(CCC1)CCN1C(c1c[s]c(-c2c(C)[nH]nc2C)c1)=O BOSQREDAJQASQH-UHFFFAOYSA-N 0.000 description 1
- PVOFBJLLCDYDBX-UHFFFAOYSA-N CC(C)(CCC1)CCN1C(c1c[s]c(-c2c(C)[o]nc2C)c1)=O Chemical compound CC(C)(CCC1)CCN1C(c1c[s]c(-c2c(C)[o]nc2C)c1)=O PVOFBJLLCDYDBX-UHFFFAOYSA-N 0.000 description 1
- JLGVXUYMNQJBSS-UHFFFAOYSA-N CC(C)(CCC1)CCN1C(c1c[s]c(-c2c[nH]nc2)c1)=O Chemical compound CC(C)(CCC1)CCN1C(c1c[s]c(-c2c[nH]nc2)c1)=O JLGVXUYMNQJBSS-UHFFFAOYSA-N 0.000 description 1
- SAVWAYCLOWKSMJ-UHFFFAOYSA-N CC(C)(CCC1)CN1C(c1c[s]c(-c2c[nH]nc2)c1)=O Chemical compound CC(C)(CCC1)CN1C(c1c[s]c(-c2c[nH]nc2)c1)=O SAVWAYCLOWKSMJ-UHFFFAOYSA-N 0.000 description 1
- IUQJFEWFLUQIQE-UHFFFAOYSA-N CC(C1)(C2)CC(C)(C)CC1N2C(c1c[s]c(-c2c(C)[nH]nc2C)c1)=O Chemical compound CC(C1)(C2)CC(C)(C)CC1N2C(c1c[s]c(-c2c(C)[nH]nc2C)c1)=O IUQJFEWFLUQIQE-UHFFFAOYSA-N 0.000 description 1
- WVNOZHITHZEVLL-UHFFFAOYSA-N CC(C1)(C2)CC(C)(C)CC1N2C(c1c[s]c(-c2c(C)[o]nc2C)c1)=O Chemical compound CC(C1)(C2)CC(C)(C)CC1N2C(c1c[s]c(-c2c(C)[o]nc2C)c1)=O WVNOZHITHZEVLL-UHFFFAOYSA-N 0.000 description 1
- ODFHNNBHLRSRJV-UHFFFAOYSA-N CC(C1)(C2)CC(C)(C)CC1N2C(c1c[s]c(-c2c[nH]nc2)c1)=O Chemical compound CC(C1)(C2)CC(C)(C)CC1N2C(c1c[s]c(-c2c[nH]nc2)c1)=O ODFHNNBHLRSRJV-UHFFFAOYSA-N 0.000 description 1
- MZYCNHHMAROHBY-UHFFFAOYSA-N CC(C1)(C2)CC(C)(C)CC1N2C(c1c[s]c(-c2ccncc2)c1)=O Chemical compound CC(C1)(C2)CC(C)(C)CC1N2C(c1c[s]c(-c2ccncc2)c1)=O MZYCNHHMAROHBY-UHFFFAOYSA-N 0.000 description 1
- AMWCLCIMCAZNBB-UHFFFAOYSA-N CC(CCCC1)N1C(c1c[s]c(-c2c[nH]nc2)c1)=O Chemical compound CC(CCCC1)N1C(c1c[s]c(-c2c[nH]nc2)c1)=O AMWCLCIMCAZNBB-UHFFFAOYSA-N 0.000 description 1
- WACYTCDCBQXUAW-UHFFFAOYSA-N CC1(C)CN(C)CC1 Chemical compound CC1(C)CN(C)CC1 WACYTCDCBQXUAW-UHFFFAOYSA-N 0.000 description 1
- PGERUXBLYIRESD-UHFFFAOYSA-N CC1(C)CN(C)CCC1 Chemical compound CC1(C)CN(C)CCC1 PGERUXBLYIRESD-UHFFFAOYSA-N 0.000 description 1
- RTMBVIAUHVXGJX-UHFFFAOYSA-N CC1(C)CN(C)CCCC1 Chemical compound CC1(C)CN(C)CCCC1 RTMBVIAUHVXGJX-UHFFFAOYSA-N 0.000 description 1
- ZMJDNMLWLIQAFG-UHFFFAOYSA-N CC1(C)N(C)CCCCC1 Chemical compound CC1(C)N(C)CCCCC1 ZMJDNMLWLIQAFG-UHFFFAOYSA-N 0.000 description 1
- SCVLFMRHMWEYGL-UHFFFAOYSA-N CC1CN(C)CCC(C)(C)C1 Chemical compound CC1CN(C)CCC(C)(C)C1 SCVLFMRHMWEYGL-UHFFFAOYSA-N 0.000 description 1
- XIMAMXHEWOZFQC-UHFFFAOYSA-N CC1CN(C)CCCC1 Chemical compound CC1CN(C)CCCC1 XIMAMXHEWOZFQC-UHFFFAOYSA-N 0.000 description 1
- MWUISCCBFHLWLY-UHFFFAOYSA-N CC1N(C)CCCC1 Chemical compound CC1N(C)CCCC1 MWUISCCBFHLWLY-UHFFFAOYSA-N 0.000 description 1
- APYRBZPIZCOBGG-UHFFFAOYSA-N CCC(C1[N]#CC=CC1)N(C)CC Chemical compound CCC(C1[N]#CC=CC1)N(C)CC APYRBZPIZCOBGG-UHFFFAOYSA-N 0.000 description 1
- ICRRLJOENSREGK-UHFFFAOYSA-N CCCCC(CNNC)OC Chemical compound CCCCC(CNNC)OC ICRRLJOENSREGK-UHFFFAOYSA-N 0.000 description 1
- YZGILRUKSIEKQC-UHFFFAOYSA-N CCOC1CN(C)CCC1 Chemical compound CCOC1CN(C)CCC1 YZGILRUKSIEKQC-UHFFFAOYSA-N 0.000 description 1
- JNHWTQJQUIYYNR-UHFFFAOYSA-N CN(C)N(CC1)CCC1c1ccccc1 Chemical compound CN(C)N(CC1)CCC1c1ccccc1 JNHWTQJQUIYYNR-UHFFFAOYSA-N 0.000 description 1
- QFAWAVGPCISLLW-UHFFFAOYSA-N CN(CC1)C(CCCC2)C2N1C(c1c[s]c(-c2c[nH]nc2)c1)=O Chemical compound CN(CC1)C(CCCC2)C2N1C(c1c[s]c(-c2c[nH]nc2)c1)=O QFAWAVGPCISLLW-UHFFFAOYSA-N 0.000 description 1
- YDNBZEZHOYJIKQ-UHFFFAOYSA-N CN(CC1)CC1c1ccccc1 Chemical compound CN(CC1)CC1c1ccccc1 YDNBZEZHOYJIKQ-UHFFFAOYSA-N 0.000 description 1
- FYYHCAFENCIKGE-UHFFFAOYSA-N CN(CC1)CCC1(F)[I]=C Chemical compound CN(CC1)CCC1(F)[I]=C FYYHCAFENCIKGE-UHFFFAOYSA-N 0.000 description 1
- AGGVOBMIIGKVIE-UHFFFAOYSA-N CN(CCC1)C1c1ccc[s]1 Chemical compound CN(CCC1)C1c1ccc[s]1 AGGVOBMIIGKVIE-UHFFFAOYSA-N 0.000 description 1
- DMRUVRQCQAKJTQ-UHFFFAOYSA-N CN(CCC1)C1c1ccncc1 Chemical compound CN(CCC1)C1c1ccncc1 DMRUVRQCQAKJTQ-UHFFFAOYSA-N 0.000 description 1
- GLXOHWLGZMRLRM-UHFFFAOYSA-N CN(CCC1)CCC1O Chemical compound CN(CCC1)CCC1O GLXOHWLGZMRLRM-UHFFFAOYSA-N 0.000 description 1
- MMYMNCSSJLHIES-UHFFFAOYSA-N CN(CCC1)CCCC1(F)F Chemical compound CN(CCC1)CCCC1(F)F MMYMNCSSJLHIES-UHFFFAOYSA-N 0.000 description 1
- VTPZFHKUAXRISN-UHFFFAOYSA-N CN(CCCC1)C1c1ccncc1 Chemical compound CN(CCCC1)C1c1ccncc1 VTPZFHKUAXRISN-UHFFFAOYSA-N 0.000 description 1
- QIRIHMCWPZKHGZ-UHFFFAOYSA-N CN(CCCC1)CC1O Chemical compound CN(CCCC1)CC1O QIRIHMCWPZKHGZ-UHFFFAOYSA-N 0.000 description 1
- RTAYRRLXJXJDBM-UHFFFAOYSA-N CN(CCCCC1)C1c1ccccn1 Chemical compound CN(CCCCC1)C1c1ccccn1 RTAYRRLXJXJDBM-UHFFFAOYSA-N 0.000 description 1
- FUSVJRCGZGBIBW-UHFFFAOYSA-N CN(CCCCC1)CC1c1ccccc1 Chemical compound CN(CCCCC1)CC1c1ccccc1 FUSVJRCGZGBIBW-UHFFFAOYSA-N 0.000 description 1
- DCJOATWQZLCBDY-UHFFFAOYSA-N CN(CCN(CC(F)(F)F)C1)C1C1CC=CCC1 Chemical compound CN(CCN(CC(F)(F)F)C1)C1C1CC=CCC1 DCJOATWQZLCBDY-UHFFFAOYSA-N 0.000 description 1
- VYLGWVNPNMMXFQ-UHFFFAOYSA-N CN1C(CC2)CCN2CC1 Chemical compound CN1C(CC2)CCN2CC1 VYLGWVNPNMMXFQ-UHFFFAOYSA-N 0.000 description 1
- OBCQEKHFXPRIMA-UHFFFAOYSA-N CN1C(COC2C=CC=CC2)CCC1 Chemical compound CN1C(COC2C=CC=CC2)CCC1 OBCQEKHFXPRIMA-UHFFFAOYSA-N 0.000 description 1
- IRWBEXAXTYLLPN-UHFFFAOYSA-N COc(nc1)ccc1-c1cc(C(N2C(CCCC3)C3CCC2)=O)c[s]1 Chemical compound COc(nc1)ccc1-c1cc(C(N2C(CCCC3)C3CCC2)=O)c[s]1 IRWBEXAXTYLLPN-UHFFFAOYSA-N 0.000 description 1
- ZPMJNSVWEOCLRU-UHFFFAOYSA-N C[n]1ncc(-c2cc(C(N3CCCCC3)=O)c[s]2)c1 Chemical compound C[n]1ncc(-c2cc(C(N3CCCCC3)=O)c[s]2)c1 ZPMJNSVWEOCLRU-UHFFFAOYSA-N 0.000 description 1
- LCVKXUZCCKENBT-UHFFFAOYSA-N Cc1n[o]c(C)c1-c1cc(C(N(CCCC2)C2c2ccccc2)=O)c[s]1 Chemical compound Cc1n[o]c(C)c1-c1cc(C(N(CCCC2)C2c2ccccc2)=O)c[s]1 LCVKXUZCCKENBT-UHFFFAOYSA-N 0.000 description 1
- JHMAOUBTKCQMAP-UHFFFAOYSA-N Nc1ncc(-c2cc(C(N3C(CCCC4)C4CCC3)=O)c[s]2)[o]1 Chemical compound Nc1ncc(-c2cc(C(N3C(CCCC4)C4CCC3)=O)c[s]2)[o]1 JHMAOUBTKCQMAP-UHFFFAOYSA-N 0.000 description 1
- WNKLRISZVWZAJC-UHFFFAOYSA-N O=C(c1c[s]c(-[n]2cncc2)c1)N1C(CCCC2)C2CCC1 Chemical compound O=C(c1c[s]c(-[n]2cncc2)c1)N1C(CCCC2)C2CCC1 WNKLRISZVWZAJC-UHFFFAOYSA-N 0.000 description 1
- OIMNQDJUMFBNPG-UHFFFAOYSA-N O=C(c1c[s]c(-[n]2nccc2)c1)N1C(CCCC2)C2CCC1 Chemical compound O=C(c1c[s]c(-[n]2nccc2)c1)N1C(CCCC2)C2CCC1 OIMNQDJUMFBNPG-UHFFFAOYSA-N 0.000 description 1
- KESGHDCYFUFATL-UHFFFAOYSA-N O=C(c1c[s]c(-c(cn2)ccc2F)c1)N1C(CCCC2)C2CCC1 Chemical compound O=C(c1c[s]c(-c(cn2)ccc2F)c1)N1C(CCCC2)C2CCC1 KESGHDCYFUFATL-UHFFFAOYSA-N 0.000 description 1
- XJLMLBHOEBOANW-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]cn2)c1)N1C(CCCC2)C2CCC1 Chemical compound O=C(c1c[s]c(-c2c[nH]cn2)c1)N1C(CCCC2)C2CCC1 XJLMLBHOEBOANW-UHFFFAOYSA-N 0.000 description 1
- TUJSOMCBXCTPBS-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CC1)CC1c1ccccc1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CC1)CC1c1ccccc1 TUJSOMCBXCTPBS-UHFFFAOYSA-N 0.000 description 1
- ORIACTWYCKXOAB-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CC1)CCC1c1ccccc1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CC1)CCC1c1ccccc1 ORIACTWYCKXOAB-UHFFFAOYSA-N 0.000 description 1
- DVDZQYYKIHGVAY-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)C1C(F)(F)F Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)C1C(F)(F)F DVDZQYYKIHGVAY-UHFFFAOYSA-N 0.000 description 1
- CKEVECSZVLUCNQ-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)C1c(cc1)ccc1I Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)C1c(cc1)ccc1I CKEVECSZVLUCNQ-UHFFFAOYSA-N 0.000 description 1
- JLTCNAHQABXRNN-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)C1c1ccc[s]1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)C1c1ccc[s]1 JLTCNAHQABXRNN-UHFFFAOYSA-N 0.000 description 1
- QJEYFCDWJWELNA-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)C1c1ccccc1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)C1c1ccccc1 QJEYFCDWJWELNA-UHFFFAOYSA-N 0.000 description 1
- PDRROCMIHLBJKB-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)C1c1ccccc1Cl Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)C1c1ccccc1Cl PDRROCMIHLBJKB-UHFFFAOYSA-N 0.000 description 1
- OLIRUVSXIHFGJN-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)C1c1cnccc1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)C1c1cnccc1 OLIRUVSXIHFGJN-UHFFFAOYSA-N 0.000 description 1
- JFNQNOWSQKHERK-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)CC1Oc1ccccc1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)CC1Oc1ccccc1 JFNQNOWSQKHERK-UHFFFAOYSA-N 0.000 description 1
- SYAIXSSCXCJOBV-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)CC1c1ccccc1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)CC1c1ccccc1 SYAIXSSCXCJOBV-UHFFFAOYSA-N 0.000 description 1
- MLCCHOADVLJLAM-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCC1)C1c(cc1)ccc1F Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCC1)C1c(cc1)ccc1F MLCCHOADVLJLAM-UHFFFAOYSA-N 0.000 description 1
- WHCZFLXLGQCMGG-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCC1)C1c1ccccc1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCC1)C1c1ccccc1 WHCZFLXLGQCMGG-UHFFFAOYSA-N 0.000 description 1
- VVICTVHOMADAIR-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCC1)C1c1ccccn1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCC1)C1c1ccccn1 VVICTVHOMADAIR-UHFFFAOYSA-N 0.000 description 1
- WCYIHXJXTDIKKI-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCC1)C1c1cccnc1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCC1)C1c1cccnc1 WCYIHXJXTDIKKI-UHFFFAOYSA-N 0.000 description 1
- MLCCHOADVLJLAM-KRWDZBQOSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCC1)[C@@H]1c(cc1)ccc1F Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCC1)[C@@H]1c(cc1)ccc1F MLCCHOADVLJLAM-KRWDZBQOSA-N 0.000 description 1
- MLCCHOADVLJLAM-QGZVFWFLSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCC1)[C@H]1c(cc1)ccc1F Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCC1)[C@H]1c(cc1)ccc1F MLCCHOADVLJLAM-QGZVFWFLSA-N 0.000 description 1
- LXZIYBIIPCQZLT-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCCC1)C1c1ccccc1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCCC1)C1c1ccccc1 LXZIYBIIPCQZLT-UHFFFAOYSA-N 0.000 description 1
- MSRXJHNJTAWFKG-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCCC1)C1c1ccccn1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCCCC1)C1c1ccccn1 MSRXJHNJTAWFKG-UHFFFAOYSA-N 0.000 description 1
- FWBQUUBAUWHBBE-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCOC1)C1c(cc1)ccc1F Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCOC1)C1c(cc1)ccc1F FWBQUUBAUWHBBE-UHFFFAOYSA-N 0.000 description 1
- UWNBCOQGZLSAEO-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCOC1)C1c1ccccc1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCOC1)C1c1ccccc1 UWNBCOQGZLSAEO-UHFFFAOYSA-N 0.000 description 1
- ATBIPQVOZIVMTP-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCSC1)C1c(cc1)ccc1F Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N(CCSC1)C1c(cc1)ccc1F ATBIPQVOZIVMTP-UHFFFAOYSA-N 0.000 description 1
- CDKYAOJWQPQECQ-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N1C(CCCC2)C2CCC1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N1C(CCCC2)C2CCC1 CDKYAOJWQPQECQ-UHFFFAOYSA-N 0.000 description 1
- PFYNFIWDGFJWDP-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N1C(CCCC2)C2N(CC(F)(F)F)CC1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N1C(CCCC2)C2N(CC(F)(F)F)CC1 PFYNFIWDGFJWDP-UHFFFAOYSA-N 0.000 description 1
- BZMXRQCRJIINJK-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N1C(CCCC2)C2NCC1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N1C(CCCC2)C2NCC1 BZMXRQCRJIINJK-UHFFFAOYSA-N 0.000 description 1
- JGCFSPPNCGZRTP-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N1C(CCCC2)C2OCC1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N1C(CCCC2)C2OCC1 JGCFSPPNCGZRTP-UHFFFAOYSA-N 0.000 description 1
- KXZZPEKETGBBOP-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N1C(Cc2ccccc2)CCC1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N1C(Cc2ccccc2)CCC1 KXZZPEKETGBBOP-UHFFFAOYSA-N 0.000 description 1
- KDXWVWLONWXLPA-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N1C(Cc2ccccc2)CCCC1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N1C(Cc2ccccc2)CCCC1 KDXWVWLONWXLPA-UHFFFAOYSA-N 0.000 description 1
- OPSDYQIFWHEHMW-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N1CC(CCCC2)N2CC1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N1CC(CCCC2)N2CC1 OPSDYQIFWHEHMW-UHFFFAOYSA-N 0.000 description 1
- QPCJANMQKXNSSI-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N1CC(Cc2ccccc2)CC1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N1CC(Cc2ccccc2)CC1 QPCJANMQKXNSSI-UHFFFAOYSA-N 0.000 description 1
- XLWKVBCRWLCYNE-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N1CC2OCCOC2CC1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N1CC2OCCOC2CC1 XLWKVBCRWLCYNE-UHFFFAOYSA-N 0.000 description 1
- VJVWBUGKWLIZDB-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N1CCC(CC(F)(F)F)CCC1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N1CCC(CC(F)(F)F)CCC1 VJVWBUGKWLIZDB-UHFFFAOYSA-N 0.000 description 1
- KKOMHEJXVDAYOD-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N1CCCCCC1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N1CCCCCC1 KKOMHEJXVDAYOD-UHFFFAOYSA-N 0.000 description 1
- RUNWOHVLHOOIEE-KRWDZBQOSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N1[C@@H](Cc2ccccc2)COCC1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N1[C@@H](Cc2ccccc2)COCC1 RUNWOHVLHOOIEE-KRWDZBQOSA-N 0.000 description 1
- PTRTXUGOBYBMPS-INIZCTEOSA-N O=C(c1c[s]c(-c2c[nH]nc2)c1)N1[C@H](COc2ccccc2)CCC1 Chemical compound O=C(c1c[s]c(-c2c[nH]nc2)c1)N1[C@H](COc2ccccc2)CCC1 PTRTXUGOBYBMPS-INIZCTEOSA-N 0.000 description 1
- COJVCALBYQFJGM-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[o]cn2)c1)N(CCC1)C1c(cc1)ccc1F Chemical compound O=C(c1c[s]c(-c2c[o]cn2)c1)N(CCC1)C1c(cc1)ccc1F COJVCALBYQFJGM-UHFFFAOYSA-N 0.000 description 1
- BPGKCUQAGJWAFA-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[o]cn2)c1)N(CCC1)CCC1(F)F Chemical compound O=C(c1c[s]c(-c2c[o]cn2)c1)N(CCC1)CCC1(F)F BPGKCUQAGJWAFA-UHFFFAOYSA-N 0.000 description 1
- SDUVPWHFPGRTCF-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[o]cn2)c1)N(CCCC1)C1c(cc1)ccc1F Chemical compound O=C(c1c[s]c(-c2c[o]cn2)c1)N(CCCC1)C1c(cc1)ccc1F SDUVPWHFPGRTCF-UHFFFAOYSA-N 0.000 description 1
- XIQGXLVMMDKKIE-UHFFFAOYSA-N O=C(c1c[s]c(-c2c[o]cn2)c1)N1C(CCCC2)C2CCC1 Chemical compound O=C(c1c[s]c(-c2c[o]cn2)c1)N1C(CCCC2)C2CCC1 XIQGXLVMMDKKIE-UHFFFAOYSA-N 0.000 description 1
- OLLJXPVHCCXXQC-UHFFFAOYSA-N O=C(c1c[s]c(-c2cc(F)ncc2)c1)N1C(CCCC2)C2CCC1 Chemical compound O=C(c1c[s]c(-c2cc(F)ncc2)c1)N1C(CCCC2)C2CCC1 OLLJXPVHCCXXQC-UHFFFAOYSA-N 0.000 description 1
- CJSWFPKIOOEDJO-UHFFFAOYSA-N O=C(c1c[s]c(-c2cc3cccnc3cc2)c1)N1CCCCC1 Chemical compound O=C(c1c[s]c(-c2cc3cccnc3cc2)c1)N1CCCCC1 CJSWFPKIOOEDJO-UHFFFAOYSA-N 0.000 description 1
- IYZIEQGJBUXIIV-UHFFFAOYSA-N O=C(c1c[s]c(-c2cccnc2)c1)N1CCCCC1 Chemical compound O=C(c1c[s]c(-c2cccnc2)c1)N1CCCCC1 IYZIEQGJBUXIIV-UHFFFAOYSA-N 0.000 description 1
- WGODLCOMHZABPV-UHFFFAOYSA-N O=C(c1c[s]c(-c2ccncc2)c1)N1CCCCCC1 Chemical compound O=C(c1c[s]c(-c2ccncc2)c1)N1CCCCCC1 WGODLCOMHZABPV-UHFFFAOYSA-N 0.000 description 1
- SSEFMCBCHOLHRG-UHFFFAOYSA-N O=C(c1c[s]c(-c2cncnc2)c1)N1C(CCCC2)C2CCC1 Chemical compound O=C(c1c[s]c(-c2cncnc2)c1)N1C(CCCC2)C2CCC1 SSEFMCBCHOLHRG-UHFFFAOYSA-N 0.000 description 1
- RVTBJDKUYFDRDT-UHFFFAOYSA-N O=C(c1c[s]c(-c2cncnc2)c1)N1CCCCC1 Chemical compound O=C(c1c[s]c(-c2cncnc2)c1)N1CCCCC1 RVTBJDKUYFDRDT-UHFFFAOYSA-N 0.000 description 1
- MCBRIKXOIFVNMU-UHFFFAOYSA-N O=C(c1c[s]c(-c2n[nH]cc2)c1)N1C(CCCC2)C2CCC1 Chemical compound O=C(c1c[s]c(-c2n[nH]cc2)c1)N1C(CCCC2)C2CCC1 MCBRIKXOIFVNMU-UHFFFAOYSA-N 0.000 description 1
- IJYWDLZEIVRCON-UHFFFAOYSA-N OC(CCC1)CCN1C(c1c[s]c(-c2c[nH]nc2)c1)=O Chemical compound OC(CCC1)CCN1C(c1c[s]c(-c2c[nH]nc2)c1)=O IJYWDLZEIVRCON-UHFFFAOYSA-N 0.000 description 1
- XXYWYHDPHGLDJE-UHFFFAOYSA-N OC(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)C1c1ccccn1 Chemical compound OC(c1c[s]c(-c2c[nH]nc2)c1)N(CCC1)C1c1ccccn1 XXYWYHDPHGLDJE-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3611108P | 2008-03-13 | 2008-03-13 | |
| GB0804685.6 | 2008-03-13 | ||
| GBGB0804685.6A GB0804685D0 (en) | 2008-03-13 | 2008-03-13 | Therapeutic compounds and their use |
| US61/036,111 | 2008-03-13 | ||
| PCT/GB2009/000686 WO2009112845A1 (en) | 2008-03-13 | 2009-03-13 | Amido-thiophene compounds and their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011513476A JP2011513476A (ja) | 2011-04-28 |
| JP2011513476A5 true JP2011513476A5 (https=) | 2012-04-26 |
| JP5570435B2 JP5570435B2 (ja) | 2014-08-13 |
Family
ID=39328066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550262A Active JP5570435B2 (ja) | 2008-03-13 | 2009-03-13 | アミド−チオフェン化合物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8299063B2 (https=) |
| EP (1) | EP2283004B1 (https=) |
| JP (1) | JP5570435B2 (https=) |
| KR (1) | KR101626627B1 (https=) |
| AU (1) | AU2009224017B2 (https=) |
| CA (1) | CA2716679C (https=) |
| DK (1) | DK2283004T3 (https=) |
| ES (1) | ES2545489T3 (https=) |
| GB (1) | GB0804685D0 (https=) |
| IL (1) | IL208081A (https=) |
| WO (1) | WO2009112845A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0724251D0 (en) | 2007-12-12 | 2008-02-06 | Univ Edinburgh | Therapeutic compounds and their use |
| GB0804685D0 (en) | 2008-03-13 | 2008-04-16 | Univ Edinburgh | Therapeutic compounds and their use |
| EP2349269A4 (en) * | 2008-10-21 | 2012-04-25 | Merck Sharp & Dohme | 2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS |
| EP2443113A1 (en) * | 2009-06-15 | 2012-04-25 | The University Of Edinburgh | Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders |
| EP2477983B1 (en) * | 2009-09-16 | 2015-04-15 | The University Of Edinburgh | (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use |
| US9051296B2 (en) | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011135276A1 (en) * | 2010-04-29 | 2011-11-03 | The University Of Edinburgh | 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -hsd1 |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2012052412A1 (de) | 2010-10-22 | 2012-04-26 | Bayer Cropscience Ag | Neue heterocylische verbindungen als schädlingsbekämpfungsmittel |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP3373920A4 (en) | 2015-11-13 | 2019-07-17 | Pietro Paolo Sanna | METHOD AND COMPOSITIONS FOR TREATING ALCOHOL CONSUMPTION MALFUNCTIONS |
| CN106854189A (zh) * | 2015-12-08 | 2017-06-16 | 湖南华腾制药有限公司 | 一种哌嗪化合物的合成方法 |
| WO2018177993A1 (de) | 2017-03-31 | 2018-10-04 | Bayer Cropscience Aktiengesellschaft | Pyrazole zur bekämpfung von arthropoden |
| BR112019020499B1 (pt) | 2017-03-31 | 2023-12-05 | Bayer Cropscience Aktiengesellschaft | Carboxamidas tricíclicas para controlar artrópodes, seus usos e seus intermediários, composição inseticida, e método para proteção de semente transgênica ou convencional |
| WO2019134985A1 (en) * | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087631A (en) | 1990-12-18 | 1992-02-11 | Glaxo Inc. | Oxathi(SIV)azol-5-one compounds |
| AR011913A1 (es) * | 1997-03-06 | 2000-09-13 | Yamano Masaki | Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos. |
| US6303593B1 (en) * | 1999-03-02 | 2001-10-16 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
| AU2002353716A1 (en) | 2001-11-22 | 2003-06-10 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| SE0202430D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| CA2501611A1 (en) * | 2002-10-11 | 2004-04-22 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
| US7700583B2 (en) * | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
| GB0325745D0 (en) | 2003-11-05 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
| GB0326029D0 (en) | 2003-11-07 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
| RU2006146608A (ru) | 2004-06-09 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ |
| EP1894919B1 (en) | 2005-06-07 | 2012-03-28 | Shionogi & Co., Ltd. | Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity |
| US7803806B2 (en) * | 2005-11-03 | 2010-09-28 | Sgx Pharmaceuticals, Inc. | Pyrimidinyl-thiophene kinase modulators |
| BRPI0710479A2 (pt) * | 2006-01-18 | 2012-08-14 | Hoffmann La Roche | composto, processo para sua preparaÇço, composiÇço farmacÊutica, uso de um composto e mÉtodo de tratamento de doenÇa ou desosrdem metabàlica. |
| UA95480C2 (uk) | 2006-06-08 | 2011-08-10 | Елі Ліллі Енд Компані | Заміщені карбоксаміди |
| US7666888B2 (en) | 2006-07-20 | 2010-02-23 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 |
| GB0724251D0 (en) | 2007-12-12 | 2008-02-06 | Univ Edinburgh | Therapeutic compounds and their use |
| US20100022590A1 (en) | 2008-01-17 | 2010-01-28 | Biovitrum Ab (Publ.) | Novel compounds |
| GB0804685D0 (en) | 2008-03-13 | 2008-04-16 | Univ Edinburgh | Therapeutic compounds and their use |
| CA2735204C (en) | 2008-08-25 | 2017-06-20 | Boehringer Ingelheim International Gmbh | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use |
| EP2443113A1 (en) | 2009-06-15 | 2012-04-25 | The University Of Edinburgh | Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders |
| EP2477983B1 (en) | 2009-09-16 | 2015-04-15 | The University Of Edinburgh | (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use |
| WO2011135276A1 (en) | 2010-04-29 | 2011-11-03 | The University Of Edinburgh | 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -hsd1 |
-
2008
- 2008-03-13 GB GBGB0804685.6A patent/GB0804685D0/en not_active Ceased
-
2009
- 2009-03-13 JP JP2010550262A patent/JP5570435B2/ja active Active
- 2009-03-13 KR KR1020107022050A patent/KR101626627B1/ko active Active
- 2009-03-13 EP EP09718896.5A patent/EP2283004B1/en active Active
- 2009-03-13 CA CA2716679A patent/CA2716679C/en active Active
- 2009-03-13 WO PCT/GB2009/000686 patent/WO2009112845A1/en not_active Ceased
- 2009-03-13 AU AU2009224017A patent/AU2009224017B2/en active Active
- 2009-03-13 US US12/920,774 patent/US8299063B2/en active Active
- 2009-03-13 DK DK09718896.5T patent/DK2283004T3/en active
- 2009-03-13 ES ES09718896.5T patent/ES2545489T3/es active Active
-
2010
- 2010-09-12 IL IL208081A patent/IL208081A/en active IP Right Grant
-
2012
- 2012-09-13 US US13/615,497 patent/US8614209B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513476A5 (https=) | ||
| JP2013527162A5 (https=) | ||
| Beijer et al. | Strong dimerization of ureidopyrimidones via quadruple hydrogen bonding | |
| JP2013504613A5 (https=) | ||
| AU2018236691B2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| TW414792B (en) | An arylethensulfonamide derivative having endothelin receptor antagonistic effect and its pharmaceutical composition | |
| TW200461B (https=) | ||
| RU2002107203A (ru) | Производные N-гетероциклических соединений в качестве ингибиторов синтазы оксида азота (nos) | |
| JP2008513516A5 (https=) | ||
| TW200422294A (en) | Dioxan-2-ylalkylcarbamate derivatives, their preparation and their use in therapeutics | |
| JP2008521829A5 (https=) | ||
| JP2007500720A5 (https=) | ||
| DE69833297T2 (de) | Substituierte Pyridylmethylpiperazin- und piperidinderivate, deren Herstellung und deren Verwendung in der Behandlung von Erkrankungen des Zentralnervensystems (ZNS) | |
| JPWO2016031987A1 (ja) | オートタキシン阻害活性を有するピリミジノン誘導体 | |
| CA2797533A1 (en) | Compounds that modulate intracellular calcium | |
| JP2008525363A (ja) | プロスタグランジン媒介疾患治療のためのピリジン化合物 | |
| FR2876692A1 (fr) | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique | |
| EP4452968A1 (en) | Bicyclic indazole glucocorticoid receptor antagonists | |
| JP2016508152A (ja) | Ｃｒａｃチャネル阻害薬としての、ピラゾリルをベースとするカルボキサミド類ｉ | |
| JPWO2001036402A1 (ja) | 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体 | |
| Medebielle et al. | Syntheses of new difluoromethylene benzoxazole and 1, 2, 4-oxadiazole derivatives, as potent non-nucleoside HIV-1 reverse transcriptase inhibitors | |
| WO1990005132A1 (fr) | Derives d'allylamine substitues, procede de preparation et utilisation | |
| JP2001072660A (ja) | ＴＮＦ−α産生抑制剤および／またはＩＬ−１０産生促進剤 | |
| CN101137644A (zh) | 7-（2-（4-（3-三氟甲基-苯基）-1,2,3,6-四氢-吡啶-1-基）乙基）异喹啉苯磺酸盐、它的制备与治疗用途 | |
| WO2024192416A1 (en) | Dpp1 inhibitors with polycyclic linkers and uses thereof |